Breakthrough Devices Program

What is the Breakthrough Devices Program?

The program is designed to provide patients and healthcare providers with timely access to qualifying devices by prioritizing their review and offering sponsors more interactive communication with FDA review teams. Tools can include sprint discussions, agreement on data-development plans and senior management engagement during development and review.

Which devices qualify?

Two statutory criteria apply. First, the device must provide for more effective treatment or diagnosis of a life-threatening or irreversibly debilitating disease or condition. Second, it must meet at least one additional criterion: breakthrough technology; no approved or cleared alternative; significant advantages over existing alternatives; or availability in the best interest of patients. The sponsor may request designation before submitting a PMA, De Novo request or 510(k), and the FDA states a 60-calendar-day designation decision timeframe.

What does designation actually change?

Interaction and priority — not the authorization standard. A breakthrough PMA, De Novo or 510(k) must still satisfy the statutory criteria for approval, granting or clearance. The program can make evidence planning more iterative and give the later marketing submission priority review, but it does not guarantee a shorter total development timeline, a favorable decision, coverage or payment. Those downstream questions follow their own payer and reimbursement processes.

Is designation public?

The FDA publishes program statistics and a list of devices authorized after receiving designation, but it generally does not disclose a designation before marketing authorization; sponsors may choose to announce it. Public claims must distinguish designation from authorization. For a United States strategy, the practical value is earlier and more structured FDA engagement around a qualifying device, not permission to market it.